Goldman Sachs’s PDS Biotechnology PDSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-317,460
Closed -$930K 6007
2024
Q2
$930K Buy
317,460
+226,986
+251% +$726K ﹤0.01% 4456
2024
Q1
$358K Buy
90,474
+77,988
+625% +$402K ﹤0.01% 4892
2023
Q4
$62.1K Sell
12,486
-836
-6% -$4.16K ﹤0.01% 5354
2023
Q3
$67.3K Sell
13,322
-14,376
-52% -$78.7K ﹤0.01% 5243
2023
Q2
$139K Sell
27,698
-57,473
-67% -$376K ﹤0.01% 5292
2023
Q1
$524K Buy
+85,171
New +$697K ﹤0.01% 4791
2022
Q2
Sell
-29,752
Closed -$184K 6644
2022
Q1
$184K Sell
29,752
-2,010
-6% -$12.5K ﹤0.01% 5918
2021
Q4
$257K Buy
31,762
+20,367
+179% +$219K ﹤0.01% 5750
2021
Q3
$170K Buy
+11,395
New +$142K ﹤0.01% 5775
2021
Q2
Sell
-20,867
Closed -$95K 6433
2021
Q1
$95K Buy
20,867
+1,267
+6% +$5.1K ﹤0.01% 5858
2020
Q4
$42K Buy
+19,600
New +$42.9K ﹤0.01% 5396
2018
Q4
Sell
-5,344
Closed -$88K 5565
2018
Q3
$88K Sell
5,344
-1,865
-26% -$33.5K ﹤0.01% 5177
2018
Q2
$149K Buy
7,209
+6,198
+613% +$129K ﹤0.01% 5092
2018
Q1
$24K Buy
+1,011
New +$272K ﹤0.01% 5638
2017
Q3
Sell
-1,824
Closed -$374K 6797
2017
Q2
$374K Buy
+1,824
New +$359K ﹤0.01% 5319
2017
Q1
Sell
-1,445
Closed -$361K 6938
2016
Q4
$361K Buy
+1,445
New +$328K ﹤0.01% 5334
2016
Q3
Sell
-2,239
Closed -$453K 7134
2016
Q2
$453K Buy
+2,239
New +$396K ﹤0.01% 4933

Other funds holding PDSB

Goldman Sachs's PDSB Position: Q3 2024 in Review

Goldman Sachs sold out of PDS Biotechnology (PDSB) in Q3 2024, closing a stake of 317,460 shares — an estimated $930K sold.

Goldman Sachs first reported a position in PDSB in Q2 2016 and held it in 17 quarters. The position peaked at $930K in Q2 2024. 57 funds tracked by Wall St. Rank hold PDSB as of Q3 2024.

  • Goldman Sachs reported no remaining PDS Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 317,460 PDS Biotechnology shares in Q3 2024, an estimated $930K.
  • Goldman Sachs first reported a position in PDS Biotechnology in Q2 2016 and held it in 17 quarters.
  • Goldman Sachs's PDS Biotechnology position peaked at $930K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.